INSYS Therapeutics (INSY) Bullish View Reiterated at Piper Jaffray Following Favorable Buprenorphine Data
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Piper Jaffray analyst David Amsellem reiterated an Overweight rating and $28 price target on INSYS Therapeutics (NASDAQ: INSY) reported positive top-line results from a Phase III trial evaluating its sublingual spray form of buprenorphine for post-operative pain following bunionectomy surgery.
Amsellem commented, "We continue to believe that the product is a promising shot-on-goal not only in acute pain settings (e.g., emergency medicine, post-operative pain) but also in chronic pain (particularly considering that the molecule is uniquely positioned versus other opioids as less abuse-prone schedule III controlled substance). We believe INSY is well-positioned to deliver a long-term EPS CAGR (2017+) of at least in 25%-30%, and this only reflects contribution from Subsys and Syndros (which is set to launch later this year). This translates into an attractive risk/reward profile in the context of a 2017E P/E of 17x."
Shares of INSYS Therapeutics closed at $16.37 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Cuts Price Target on Entergy (ETR) to $74 Following new Guidance
- Wedbush Cuts Price Target on Polaris Industries (PII) Following 3Q Report
- Edwards Lifesciences (EW) PT Lowered to $114 at Stifel, 'Buy' Kept
Create E-mail Alert Related CategoriesAnalyst Comments, FDA
Related EntitiesPiper Jaffray
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!